Cure My Disease

Don't miss your cure!

 Log in / Sign up

CAR-T therapy may erase vaccine immunity, new study warns

NCT ID NCT06784167

Recruiting now Knowledge-focused Sponsor: OHSU Knight Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study looks at whether CAR-T cell therapy reduces the body's ability to fight off diseases like measles and mumps that were previously prevented by vaccines. Researchers will measure antibody levels in 45 adults with multiple myeloma or non-Hodgkin lymphoma before and after CAR-T treatment. The goal is to understand if patients need to be revaccinated after this type of cancer therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors understand whether blood cancer patients need revaccination after CAR-T therapy.
What could go wrong
This is a small, observational study (45 people) that only measures immune markers, not health outcomes. Results may not apply to all patients or vaccines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia diffuse large B-cell lymphoma follicular lymphoma mantle cell lymphoma plasma cell myeloma primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA DIFFUSE LARGE B CELL LYMPHOMA FOLLICULAR LYMPHOMA MANTLE CELL LYMPHOMA MULTIPLE MYELOMA PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Locations

  • OHSU Knight Cancer Institute

    RECRUITING

    Portland, Oregon, 97239, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.